PT - JOURNAL ARTICLE AU - Anca M. Avram AU - Katherine Zukotynski AU - Helen Ruth Nadel AU - Luca M Giovanella TI - MANAGEMENT OF DIFFERENTIATED THYROID CANCER: THE STANDARD OF CARE AID - 10.2967/jnumed.121.262402 DP - 2021 Aug 01 TA - Journal of Nuclear Medicine PG - jnumed.121.262402 4099 - http://jnm.snmjournals.org/content/early/2021/08/19/jnumed.121.262402.short 4100 - http://jnm.snmjournals.org/content/early/2021/08/19/jnumed.121.262402.full AB - In the past decade the management of differentiated thyroid cancer (DTC) underwent a paradigm shift towards the use of risk-stratification with the goal of maximizing benefit and minimizing morbidity of radioiodine (131I) therapy. 131I therapy is guided by information derived from surgical histopathology, molecular markers, postoperative diagnostic radioiodine scintigraphy and thyroglobulin (Tg) levels. 131I is used for diagnostic imaging and therapy of DTC based on physiologic sodium-iodine symporter expression in normal and neoplastic thyroid tissue. We summarize the essential information at the core of multidisciplinary DTC management, which emphasizes individualization of 131I therapy according to the patient’s risk for tumor recurrence.